Lightnews — Scholar-powered news

Sally Gainsbury @sallygainsbury.bsky.social · 11h

also this older piece here silo.tips/download/key...

[PDF] Key Factors in Attracting Internationally Mobile Investments by the Research- - Free Download PDF

1 21 st September 2007 Key Factors in Attracting Internationally Mobile Investments by the Research- Based Pharmaceutica...

silo.tips

1 1

Sally Gainsbury @sallygainsbury.bsky.social · 11h

see p50 (printed p50, not pdf p50...) here efpia.eu/media/676753...

efpia.eu

1

Sally Gainsbury @sallygainsbury.bsky.social · 12h

Trump pressure to hike UK drug prices could cost NHS billions, experts warn

Experts warn a new deal will only trigger further increased price demands and make healthcare in the UK more expensive

www.independent.co.uk

Sally Gainsbury @sallygainsbury.bsky.social · 12h

Patent protections mean pharma cos can set prices high. The VPAG agreement at the centre of the row offers the NHS a modest counterbalance against those high prices when sales volumes exceed expectations and already contains exemptions to allow companies to recoup their R&D costs

1

Sally Gainsbury @sallygainsbury.bsky.social · 12h

There is mounting evidence that rather than being “too low” the NICE threshold (the max the NHS will pay for a yr of health gained through a drug) is currently too high as it outstrips how much health could be gained if the £ was spent instead on extending existing services >

1

Sally Gainsbury @sallygainsbury.bsky.social · 12h

Key points: Big pharma’s threat to pull investment from the UK if the NHS doesn’t pay more is based on politics, not economics. Industry’s own research shows that decisions on R&D location are driven by where you can do good science, not local market prices for the end product >

2

Sally Gainsbury @sallygainsbury.bsky.social · 12h

Trump and pharma are lobbying gov hard to water-down the NHS’s ability to contain spending on new branded drugs. Today’s long read from me and the LSE’s Huseyin Naci sets out why the gov should hold firm to protect the health of the NHS and UK public nuffieldtrust.org.uk/news-item/th... >>

The tough choices at the heart of the government’s dispute with big pharma

The government has been locked in a dispute with pharmaceutical companies for a number of months over how much the NHS pays for new branded medicines. Sally Gainsbury and Huseyin Naci set out the issu...

nuffieldtrust.org.uk

1 4 4

Sally Gainsbury @sallygainsbury.bsky.social · 5d

interesting. I wonder if the catch up at 16 seen in the overall dashed ECHP line is a genuine improvement in outcomes, or rather a widening of who is included in that cohort to include those whose edu outcomes were higher/likely to be slightly higher already?

1

Sally Gainsbury @sallygainsbury.bsky.social · 5d

this is really interesting Luke, thank you. It seems to suggest that educational outcomes (measured by the standardised score) have improved since ~2015 for the older kids on ECHPs, but declined for the younger. Or am I misinterpreting that?

1 1

Sally Gainsbury @sallygainsbury.bsky.social · Aug 25

For more on the background to the dispute with the pharma industry, see www.nuffieldtrust.org.uk/news-item/tr... ENDS

Trump, medicines and the NHS

Following recent press speculation that the UK may soon agree to pay more for drugs used within the NHS as part of a trade deal with the USA, we spoke to Mark Dayan and Sally Gainsbury to discuss the ...

www.nuffieldtrust.org.uk

Sally Gainsbury @sallygainsbury.bsky.social · Aug 25

But the gov hasn’t made things easy for itself with its rhetoric around the NHS as an engine of economic growth (rather than the quaint notion it is there to improve our health)>>

1

Sally Gainsbury @sallygainsbury.bsky.social · Aug 25

If the gov pays more for new medicines, we are highly likely to get LESS health benefit out of the NHS, not more. It’s right the gov holds firm and considers population-wide health needs rather than bow to industry threats and scare stories >>

1

Sally Gainsbury @sallygainsbury.bsky.social · Aug 25

For a summary, see www.sciencemediacentre.org/expert-react...
>>

expert reaction to study looking at population health displacement versus benefits of new drugs recommended by NICE / the NHS in England during 2000–20 | Science Media Centre

www.sciencemediacentre.org

1

Sally Gainsbury @sallygainsbury.bsky.social · Aug 25

It’s correct the £30k threshold has been in place since the late 1990s, but ample economic research shows it is likely too high rather than too low >>

1

Sally Gainsbury @sallygainsbury.bsky.social · Aug 25

This isn’t penny pinching: the threshold exists in order to ensure expensive new drugs don’t displace pre-existing treatments, because the nhs can only spend its budget once >>

1

Sally Gainsbury @sallygainsbury.bsky.social · Aug 25

Sometimes new drugs fail that test simply because they are very expensive. Other times they fail because their price might be modest, but the health improvements they offer above already existing treatments are extremely marginal >>

1

Sally Gainsbury @sallygainsbury.bsky.social · Aug 25

The nhs (via NICE) generally requires that for a new drug to be adopted, the extra health benefits it brings should not add more than £30k above existing treatments for that disease >>

1

Sally Gainsbury @sallygainsbury.bsky.social · Aug 25

More on that here www.nuffieldtrust.org.uk/news-item/an...
>>

An engine for economic growth? Why it won’t be a piece of cake for the NHS

With the newly published Life Sciences Sector Plan coming soon after the 10 Year Health Plan for England, Sally Gainsbury reflects on the government’s gamble on the NHS as a driver of economic growth ...

www.nuffieldtrust.org.uk

1

Sally Gainsbury @sallygainsbury.bsky.social · Aug 25

The 10 year nhs plan already sets out a terrifying raft of concessions to pharma and med tech to try and convince them to invest in the uk to feed the political addiction to economic growth >>

1

Sally Gainsbury @sallygainsbury.bsky.social · Aug 25

PSA that the purpose of the #NHS is NOT to provide investment opportunities or lucrative income streams for the pharmaceutical industry #r4today >>

1 3 5

Sally Gainsbury @sallygainsbury.bsky.social · Aug 19

Editorial from me and LSE’s Huseyin Naci on the government's bid to use the NHS as a means to attract more med tech and pharma investment into the UK. TLDR: great for profits, less great for getting the most value for patients out of the NHS www.bmj.com/content/390/...

1

Sally Gainsbury @sallygainsbury.bsky.social · Jul 19

Growth or bust. The one where the purpose of the NHS is to rescue capitalism: www.nuffieldtrust.org.uk/news-item/an...

An engine for economic growth? Why it won’t be a piece of cake for the NHS

With the newly published Life Sciences Sector Plan coming soon after the 10 Year Health Plan for England, Sally Gainsbury reflects on the government’s gamble on the NHS as a driver of economic growth ...

www.nuffieldtrust.org.uk

3 6

Sally Gainsbury @sallygainsbury.bsky.social · Jul 17

Thanks Dave

1

Reposted by Sally Gainsbury

Nuffield Trust @nuffieldtrust.org.uk · Jul 17

NEW: A long read from @sallygainsbury.bsky.social examines a conundrum for policy makers: How can the NHS meet public demand while also positioning the NHS as an engine for economic growth? www.nuffieldtrust.org.uk/news-item/an...

An engine for economic growth? Why it won’t be a piece of cake for the NHS

With the newly published Life Sciences Sector Plan coming soon after the 10 Year Health Plan for England, Sally Gainsbury reflects on the government’s gamble on the NHS as a driver of economic growth ...

www.nuffieldtrust.org.uk

1 5 4

Sally Gainsbury @sallygainsbury.bsky.social · Jul 17

The quaint idea the #NHS exists to improve health has been supplemented with the idea it can also drive economic #growth. My thoughts on the gamble the gov is making by inviting in more tech- and pharma- and whether we’ll end up with less as a consequence: www.nuffieldtrust.org.uk/news-item/an...

www.nuffieldtrust.org.uk

2 1